Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Opus Genetics (Nasdaq: IRD) announced that CEO George Magrath, M.D. will present at the J.P.

Rhea-AI Summary

Opus Genetics (Nasdaq: IRD) announced that CEO George Magrath, M.D. will present at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 8:15 a.m. PT.

The company is a clinical-stage biopharmaceutical developer of gene therapies for inherited retinal diseases. A live and archived webcast will be available on Opus Genetics' investor website under Events.

Argus Dec 11 session

-2.40% close to close Open Argus

Details

News Market Reaction – IRD

In the Dec 11 session, IRD declined 2.40%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Opus Genetics’ plans to present at the J.P. Morgan 2026 Healthcare Conf...

Analysis

This announcement highlights Opus Genetics’ plans to present at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026 at 8:15 a.m. PT, extending a pattern of active investor outreach following recent clinical and financial updates. Prior news included positive BEST1 safety review, progress in OPGx-LCA5, and strengthened cash resources. Investors may focus on how conference remarks elaborate on clinical timelines, funding runway, and strategic priorities for the inherited retinal disease gene therapy portfolio.

Key Figures

Conference date: January 15, 2026 Presentation time: 8:15 a.m. PT

Conference date

January 15, 2026

J.P. Morgan 2026 Healthcare Conference presentation date

Presentation time

8:15 a.m. PT

Scheduled time of JPM Healthcare Conference presentation

Historical Context

5 past events · Latest: Dec 09

5 events

1. Dec 09

   Clinical safety update

   24h Move

   +4.4%

   IDMC issued positive safety recommendation to continue BEST1 Phase 1/2 trial.

2. Dec 02

   Inducement grants

   24h Move

   -0.5%

   Equity inducement awards to new employees under Nasdaq Rule 5635(c)(4).

3. Nov 20

   Conference participation

   24h Move

   +3.8%

   Management scheduled for BTIG Ophthalmology Day and Piper Sandler conference.

4. Nov 13

   First-patient dosing

   24h Move

   -3.6%

   First participant dosed in OPGx-BEST1 Phase 1/2 gene therapy trial.

5. Nov 12

   Earnings & update

   24h Move

   -2.5%

   Q3 2025 results and positive LCA5 data with extended cash runway.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases, announced today that George Magrath, M.D., Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 8:15 a.m. PT.

A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases. The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, RDH12, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional indications in late-stage development for presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source: Opus Genetics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Opus Genetics (IRD) present at the J.P. Morgan 2026 Healthcare Conference?

Opus Genetics will present on January 15, 2026 at 8:15 a.m. PT.

Who is presenting for Opus Genetics (IRD) at the January 15, 2026 conference?

Chief Executive Officer George Magrath, M.D. will deliver the presentation.

Where can investors watch the Opus Genetics (IRD) J.P. Morgan presentation?

A live and archived webcast is available on Opus Genetics' investor website under the Events section.

What is Opus Genetics' (IRD) business focus mentioned for the J.P. Morgan 2026 appearance?

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases.

Will the Opus Genetics (IRD) webcast from J.P. Morgan be archived for later viewing?

Yes, the company said an archived webcast will be accessible on its investor website.

How can I find the Opus Genetics (IRD) webcast link for the J.P. Morgan 2026 presentation?

The webcast link will be posted under Investors → Events on the Opus Genetics website.